World's Best Scientists 2026 revealed!
Mark E. Schmidt

Mark E. Schmidt

D-Index & Metrics

Neuroscience

D-Index
40
Citations
6929
World Ranking
8062
National Ranking
96

Overview

Mark E. Schmidt is affiliated with Janssen in Belgium. Their research primarily spans the fields of Medicine and Neuroscience, with a focus on subfields such as Psychiatry and Mental Health, Physiology, Cognitive Neuroscience, Radiology, Nuclear Medicine and Imaging, and Pharmacology.

They have contributed extensively to topics including:

  • Dementia and Cognitive Impairment Research
  • Alzheimer's disease research and treatments
  • Functional Brain Connectivity Studies
  • Medical Imaging Techniques and Applications
  • Cannabis and Cannabinoid Research
  • Advanced MRI Techniques and Applications
  • Treatment of Major Depression

The body of published work by Mark E. Schmidt includes papers in prominent journals with multiple contributions to "Alzheimer's & Dementia" (17 publications) and "Neuropsychopharmacology" (4 publications), as well as works in "European Journal of Nuclear Medicine and Molecular Imaging," "NeuroImage," and "Molecular Psychiatry."

Notable recent publications authored or co-authored by Schmidt include:

  • The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study (2020), Neuropsychopharmacology
  • A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials (2021), Molecular Psychiatry
  • Multitracer model for staging cortical amyloid deposition using PET imaging (2020), Neurology
  • Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort (2021), Alzheimer's & Dementia
  • Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study (2020), Alzheimer's & Dementia

Frequent collaborators in their research include:

  • Juan Domingo Gispert
  • Frederik Barkhof
  • Pieter Jelle Visser
  • Lyduine E. Collij
  • Andrew Stephens

Best Publications

  • The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

    Michael W. Weiner;Michael W. Weiner;Dallas P. Veitch;Paul S. Aisen;Laurel A Beckett

  • The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans

    Michael W. Weiner;Michael W. Weiner;Paul S. Aisen;Clifford R. Jack;William J. Jagust

  • Reduced Reward Learning predicts outcome in Major Depressive Disorder

    Elske Vrieze;Diego A. Pizzagalli;Koen Demyttenaere;Titia Hompes

  • Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

    S. M. Landau;S. M. Landau;B. A. Thomas;L. Thurfjell;M. Schmidt

  • Human PET Studies of Metabotropic Glutamate Receptor Subtype 5 with 11C-ABP688

    Simon M. Ametamey;Valerie Treyer;Johannes Streffer;Matthias T. Wyss

  • Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

    Enchi Liu;Mark E. Schmidt;Richard Margolin;Reisa Sperling

  • Dimensions in major depressive disorder and their relevance for treatment outcome.

    Elske Vrieze;Koen Demyttenaere;Ronny Bruffaerts;Dirk Hermans

  • The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

    Mark E. Schmidt;Ping Chiao;Gregory Klein;Dawn Matthews

  • Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-β-induced pathology

    Jelle Praet;Nikolay V. Manyakov;Leacky Muchene;Zhenhua Mai;Zhenhua Mai

  • PET imaging shows loss of striatal PDE10A in patients with Huntington disease.

    Rawaha Ahmad;Sophie Bourgeois;Andrey Postnov;Mark E. Schmidt

  • Preclinical Evaluation of 18F-JNJ64349311, a Novel PET Tracer for Tau Imaging

    Lieven Denis Declercq;Frederik Rombouts;Michel Koole;Katleen Fierens

  • The effects of ECT on brain glucose: a pilot FDG PET study.

    Michael E. Henry;Mark E. Schmidt;John A. Matochik;Eve P. Stoddard

  • A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study.

    Michael E Henry;Mark E Schmidt;John Hennen;Rosemond A Villafuerte

  • Multi-tracer model for staging cortical amyloid deposition using PET imaging

    Lyduine E. Collij;Fiona Heeman;Gemma Salvadó;Silvia Ingala

  • The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.

    Mark E. Schmidt;Maurizio Fava;James M. Robinson;Rajinder Judge

  • The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study.

    Mark E. Schmidt;Michael R. Liebowitz;Murray B. Stein;Jennifer Grunfeld

  • Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort

    Silvia Ingala;Casper De Boer;Larissa A. Masselink;Ilaria Vergari

  • High Levels of Gsα in Platelets of Euthymic Patients With Bipolar Affective Disorder

    Philip B. Mitchell;Husseini K. Manji;Guang Chen;Libby Jolkovsky

  • Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates

    Dieter Ory;Sofie Celen;Rik Gijsbers;Chris Van Den Haute

  • Treatment approaches to major depressive disorder relapse. Part 1: dose increase.

    Mark E. Schmidt;Maurizio Fava;Shuyu Zhang;Jill Gonzales

  • 18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446

    Michel Koole;Mark E. Schmidt;Anja Hijzen;Paulien Ravenstijn

  • Preclinical Evaluation of 18F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain

    Sofie Celen;Michel Koole;Meri De Angelis;Ivan Sannen

  • Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study

    Michael E. Henry;Constance M. Moore;Marc J. Kaufman;David Michelson

Frequent Co-Authors

Xavier Langlois
Xavier Langlois AbbVie (Belgium)
Frederik Barkhof
Frederik Barkhof University College London
Juan Domingo Gispert
Juan Domingo Gispert Pasqual Maragall Foundation
William J. Jagust
William J. Jagust University of California, Berkeley
John A. Matochik
John A. Matochik National Institutes of Health
Valerie Treyer
Valerie Treyer University of Zurich
Alfred Buck
Alfred Buck University of Zurich
Rik Ossenkoppele
Rik Ossenkoppele Lund University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education options can open doors to diverse career pathways in neuroscience and related fields. More professionals are seeking online certificate programs that pay well to quickly boost their qualifications and earning potential. These certificates can supplement a neuroscience background and help specialize in high-demand areas like health technology or data science.

For adult learners and those managing busy schedules, there is a wide range of online classes for adults tailored to different learning needs. These programs offer flexibility, making it easier to balance studies with other responsibilities.

If your interests intersect with mental health or social work, consider exploring affordable msw programs online to expand your expertise. These programs are a cost-effective way to gain valuable credentials and move toward careers that combine neuroscience knowledge with social advocacy.

Additionally, for those interested in behavior analysis, bcba programs online offer a practical route to become a Board Certified Behavior Analyst—a role valuable in clinical, research, and educational settings.

Best Scientists Citing Mark E. Schmidt

Trending Scientists